Contacts

Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development

July 9, 2019

Under their collaborative agreement, MedinCell and Teva have selected a lead formulation for the longacting injectable mdc-ANG. Preclinical studies are expected to start this quarter.

mdc-ANG complements a range of antipsychotic products in development based on MedinCell’s
technology, including a first research product in clinical Phase 3 studies and another research product
in the late stages of preclinical development.

Session en français

Rendez-vous le lundi 5 septembre à 18h30 (CEST) pour une vidéoconférence dédiée à la présentation des résolution de l'Assemblée Générale

English session

On Monday 5, September at 6.30 pm (CEST) participate in our videoconference dedicated to the presentation of the resolutions of the General meeting

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.